• SSG&PM has been shown in clinical trials to be as safe and effective as the current standard treatment of SSG alone for 30 days in East Africa.
• SSG&PM offers a real cost effective option
  • The total drug cost of the SSG&PM combination is lower than the cost of SSG alone (44 vs 56 USD).
  • SSG&PM has a significantly shorter treatment duration than that of the standard treatment (17 days versus 30 days).
  • Reduction of treatment duration means cost savings to both health providers and patients.
  • Reduction of treatment duration is also critical to increasing patient turnover during outbreaks.
• The combination of SSG&PM has the potential to prolong the life of both drugs.

The development of SSG&PM is the result of a collaborative partnership over a period of six years that reflects the benefits of South-South and North-South collaboration in making a new treatment available to patients in need. Partners include

• DNDi
• the Leishmaniasis East Africa Platform (LEAP)
• the National Control Programmes of Kenya, Sudan, Ethiopia, and Uganda
• Médecins Sans Frontières (MSF)
• The World Health Organization (WHO)